| Drug Name |
Methylene blue |
| Drug ID |
BADD_D02475 |
| Description |
Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. Its use as an urinary tract antiseptic has also been investigated.
Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation. The drug is of potential interest for the treatment of patients with Alzheimer's disease. |
| Indications and Usage |
Methylene blue has several indications in medicine:
1. found to improve the hypotension associated with various clinical states.
2. Antiseptic in urinary tract infections.
3. Improves hypoxia and hyper dynamic circulation in cirrhosis of liver and severe hepatopulmonary syndrome.
4. Results in transient and reproducible improvement in blood pressure and cardiac function in septic shock.
5. Investigated for the treatment of Alzheimer's disease.
6. Treatment of ifofosamide induced neurotoxicity. |
| Marketing Status |
Not Available |
| ATC Code |
V03AB17; V04CG05 |
| DrugBank ID |
DB09241
|
| KEGG ID |
C00220
|
| MeSH ID |
D008751
|
| PubChem ID |
6099
|
| TTD Drug ID |
D09NYS
|
| NDC Product Code |
17223-0030; 73379-101; 69575-4026; 0517-0381; 68022-7067; 17223-0029; 0517-0371; 0517-0374; 12598-9541; 17478-504; 0517-0125; 54288-147 |
| Synonyms |
Methylene Blue | Blue, Methylene | Methylthioninium Chloride | Methylthionine Chloride | Swiss Blue | Blue, Swiss | Basic Blue 9 | Blue 9, Basic | Methylene Blue N | Blue N, Methylene | Chromosmon | Urolene Blue | Blue, Urolene |
